Improving Recovery after Major Cancer Surgery using Patient-Reported Outcomes

利用患者报告的结果改善重大癌症手术后的康复

基本信息

  • 批准号:
    9310343
  • 负责人:
  • 金额:
    $ 64.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-01 至 2020-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Increasing utilization of patient-reported outcomes (PROs) in clinical practice may lead to better postop- erative outcomes, with pain assessment and management as an excellent example. Although PROs are widely accepted in clinical research in medical and radiation oncology and are endorsed by the US Food & Drug Ad- ministration, the introduction of subjective outcomes is relatively novel in perioperative care practice― despite the fact that PROs are the best resource for defining and measuring the patient’s perspective of symp- tomatic and functional recovery after major cancer surgery and that the information they provide could poten- tially guide care during recovery. A major knowledge gap is that, although validated PRO tools exist, there are no established, user-friendly clinical methods for understanding and responding to symptom and function- al-status reports from patients after complex major surgery. The goal of our study is to establish a framework for clinical adoption of PROs, to define methods needed to interpret PRO data from the MD Anderson Symp- tom Inventory (MDASI), and to examine the MDASI’s clinical utility and patient and professional perspectives on using it in future practice. If we are successful, PROs could be added to well-defined, traditional metrics in perioperative care, such as decreased 30-day mortality, fewer complications, shortened hospital stays, and few- er hospital readmissions. The increasing inclusion of PRO portals in electronic medical record systems (such as EPIC) that can longitudinally track patient report away from the hospital make this approach feasible. Given EPIC’s decision to include the MDASI nationwide (also at MD Anderson Cancer Center), we believe we have a timely opportunity to provide the first evidence-based package to support implementation of the MDASI in perioperative care. At MD Anderson, perioperative recovery is being further improved by incorporation of an Enhanced Recovery Program (ERP) that challenges traditional surgical practices. The need to effectively com- pare ERP and traditional surgery outcomes exemplifies the urgency of this project. We propose a longitudinal clinical study, plus a survey of professionals to identify/address barriers to the use of PROs. We have assem- bled a strong multidisciplinary team from symptom research, surgical nursing, surgery, and anesthesiology to study patients undergoing surgery for gastrointestinal, gynecologic, or genitourinary cancer. Aim 1: Establish PRO-based methods to determine clinically meaningful postoperative symptom burden. Gap addressed: lack of quantitatively defined, procedure-specific symptom profiles and severity thresholds for managing moderate to severe symptoms, especially postdischarge. Aim 2: Establish PRO-based methods to evaluate postoperative functional recovery. Gap addressed: lack of empirical data on self-reported functional recovery to indicate readiness to resume planned oncology care or return to normal activities. Aim 3: Examine the utility of PROs as a postoperative outcome measure through a PRO study in patients and a “probe” observational study of cli- nicians. Gap addressed: lack of evidence about how the availability of PROs might alter clinical practice.
项目摘要/摘要 在临床实践中增加对患者报告结果(PRO)的利用可能会导致更好的停药后- 结果令人满意,疼痛评估和管理是一个很好的例子。尽管专业人士被广泛使用 在医学和放射肿瘤学的临床研究中被接受,并得到美国食品和药物管理局的认可- 在围手术期护理实践中,引入主观结果是相对新颖的。 尽管专业人士是定义和测量患者对症状的看法的最好资源- 癌症大手术后的躯体和功能恢复,他们提供的信息可能会- 在康复期间及时指导护理。一个主要的知识差距是,尽管存在经过验证的PRO工具,但 没有既定的、用户友好的临床方法来理解和应对症状和功能- 复杂大手术后患者的AL状态报告。我们研究的目标是建立一个框架 对于PRO的临床应用,定义解释MD Anderson符号的PRO数据所需的方法- TOM量表(MDASI),并检查MDASI的临床应用以及患者和专业视角 在未来的实践中使用它。如果我们成功了,专业人士可能会被添加到定义明确的传统指标中 围手术期护理,例如减少30天的死亡率,减少并发症,缩短住院时间,以及很少- 急诊室再入院。专业门户网站越来越多地纳入电子病历系统(例如 EPIC),可以纵向跟踪远离医院的患者报告,使这种方法可行。vt.给出 EPIC决定在全国范围内(也在MD安德森癌症中心)纳入MDASI,我们相信我们有一个 及时提供第一个以证据为基础的一揽子方案,以支持#年MDASI的实施 围手术期护理。在MD Anderson,围手术期的恢复通过合并一个 挑战传统外科实践的增强恢复计划(ERP)。需要有效地实现- PRARE ERP和传统手术结果说明了该项目的紧迫性。我们提出了一个纵向的 临床研究,外加对专业人士的调查,以确定/解决使用专业药物的障碍。我们有阿西姆- 拥有强大的多学科团队,从症状研究、外科护理、外科和麻醉学到 研究接受胃肠道、妇科或泌尿生殖道癌手术的患者。目标1:建立 以PRO为基础的方法确定有临床意义的术后症状负担。解决的差距:不足 量化定义的、特定于程序的症状配置文件和严重程度阈值,用于管理中度 到严重的症状,尤其是出院后。目的2:建立以PRO为基础的术后评估方法 功能恢复。解决差距:缺乏自我报告的功能恢复的经验数据来表明 准备好恢复有计划的肿瘤科护理或恢复正常活动。目标3:检查专业人员的效用 通过对患者进行PRO研究和临床“探索性”观察研究,作为术后结局的衡量标准。 内科医生。解决了差距:缺乏证据表明专业人士的可用性可能会如何改变临床实践。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xin Shelley Wang其他文献

Patient-reported outcome measures in surgical patients with upper gastrointestinal cancers: A qualitative interview study.
上消化道癌症手术患者患者报告的结果测量:定性访谈研究。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Samuel H Cass;L. Williams;Ravi Rajaram;Y. Hirata;David Rice;Ching;Matthew H G Katz;B. Badgwell;Xin Shelley Wang;N. Ikoma
  • 通讯作者:
    N. Ikoma
What Defines the Value of Minimally Invasive Surgery for Cancer Patients?
  • DOI:
    10.1245/s10434-023-14803-7
  • 发表时间:
    2023-12-20
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Yuki Hirata;Heather Lyu;Grace Li Smith;Xin Shelley Wang;Hop S. Tran Cao;Matthew H. G. Katz;Naruhiko Ikoma
  • 通讯作者:
    Naruhiko Ikoma
Validation and application of a module of the M. D. Anderson symptom inventory for measuring symptom burden in patients with gynecologic cancer (MDASI-PERI-GYN) for perioperative care
  • DOI:
    10.1016/j.clnesp.2018.03.114
  • 发表时间:
    2018-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Xin Shelley Wang;Qiuling Shi;Lori Williams;Charles Cleeland;Araceli Garcia;Pedro Tomas Ramirez;Maria Iniesta;Ashley Siverand;Larissa Meyer
  • 通讯作者:
    Larissa Meyer
Investigation of common symptoms of cancer and reliability analysis
  • DOI:
    10.1007/s11655-007-0195-5
  • 发表时间:
    2007-09-01
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Yi Zhao;Xin Shelley Wang;Ping-ping Li
  • 通讯作者:
    Ping-ping Li
A qualitative study for identifying symptom burden post liver surgery: MDASI-HEP development
  • DOI:
    10.1016/j.clnesp.2017.04.050
  • 发表时间:
    2017-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Xin Shelley Wang;Lori Williams;Qiuling Shi;Araceli Garcia Gonzalez;Bradford Kim;Nisha Narula;Catherine Davis;Thomas Aloia
  • 通讯作者:
    Thomas Aloia

Xin Shelley Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xin Shelley Wang', 18)}}的其他基金

Improving Recovery after Major Cancer Surgery using Patient-Reported Outcomes
利用患者报告的结果改善重大癌症手术后的康复
  • 批准号:
    9190529
  • 财政年份:
    2016
  • 资助金额:
    $ 64.8万
  • 项目类别:
Effectiveness of minocycline for reducing symptoms in pancreatic cancer patients
米诺环素减轻胰腺癌患者症状的有效性
  • 批准号:
    8540400
  • 财政年份:
    2012
  • 资助金额:
    $ 64.8万
  • 项目类别:
Effectiveness of minocycline for reducing symptoms in pancreatic cancer patients
米诺环素减轻胰腺癌患者症状的有效性
  • 批准号:
    8242916
  • 财政年份:
    2012
  • 资助金额:
    $ 64.8万
  • 项目类别:
Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
接受 CXRT 的 NSCLC 患者中炎症细胞因子相关的症状负担
  • 批准号:
    7532023
  • 财政年份:
    2008
  • 资助金额:
    $ 64.8万
  • 项目类别:
Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
接受 CXRT 的 NSCLC 患者中炎症细胞因子相关的症状负担
  • 批准号:
    7648219
  • 财政年份:
    2008
  • 资助金额:
    $ 64.8万
  • 项目类别:
Cytokines and Symptoms in Lung Cancer treatment
肺癌治疗中的细胞因子和症状
  • 批准号:
    7055277
  • 财政年份:
    2005
  • 资助金额:
    $ 64.8万
  • 项目类别:
Cytokines and Symptoms in Lung Cancer treatment
肺癌治疗中的细胞因子和症状
  • 批准号:
    6924905
  • 财政年份:
    2005
  • 资助金额:
    $ 64.8万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.8万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了